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Randomized, placebo-controlled trials of
dichlorphenamide in periodic paralysis
ABSTRACT
Objective: To determine the short-term and long-term effects of dichlorphenamide (DCP) on
attack frequency and quality of life in hyperkalemic (HYP) and hypokalemic (HOP) periodic
paralysis.
Methods: Two multicenter randomized, double-blind, placebo-controlled trials lasted 9 weeks
(Class I evidence), followed by a 1-year extension phase in which all participants
received DCP. Forty-four HOP and 21 HYP participants participated. The primary outcome
variable was the average number of attacks per week over the final 8 weeks of the double-
blind phase.
Results: The median attack rate was lower in HOP participants on DCP than in participants on pla-
cebo (0.3 vs 2.4, p5 0.02). The 9-week mean change in the Physical Component Summary score
of the Short Form–36 was also better in HOP participants receiving DCP (treatment effect 5
7.29 points, 95% confidence interval 2.26 to 12.32, p 5 0.006). The median attack rate was
also lower in HYP participants on DCP (0.9 vs 4.8) than in participants on placebo, but the dif-
ference in median attack rate was not significant (p 5 0.10). There were no significant effects of
DCP on muscle strength or muscle mass in either trial. The most common adverse events in both
trials were paresthesia (47% DCP vs 14% placebo, both trials combined) and confusion (19%
DCP vs 7% placebo, both trials combined).
Conclusions: DCP is effective in reducing the attack frequency, is safe, and improves quality of life
in HOP periodic paralysis.
Classification of evidence: These studies provide Class I evidence that DCP significantly reduces
attack frequency in HOP but lacked the precision to support either efficacy or lack of efficacy of
DCP in HYP. Neurology® 2016;86:1408–1416
GLOSSARY
CI 5 confidence interval; DCP 5 dichlorphenamide; HOP 5 hypokalemic periodic paralysis; HYP 5 hyperkalemic periodic
paralysis; IQR 5 interquartile range; MMT 5 manual muscle testing; PP 5 periodic paralysis; SF-36 5 Short Form-36.
The periodic paralyses (PPs) are inherited skeletal muscle channelopathies characterized by at-
tacks of weakness associated with serum potassium change, and typically triggered by exercise
followed by rest.1–3 Hypokalemic PP (HOP) is caused by mutations in CACNA1S in the
majority4,5; a small proportion (,10%) is due to SCN4A mutations.6–10 Hyperkalemic PP
(HYP) is caused by mutations in SCN4A.11,12 Although the PP are seldom fatal, they cause
major disability and persistent interattack weakness may develop.13,14 There is no established
standardized treatment.15–18
It has been suggested that dichlorphenamide (DCP) may be more effective than acetazola-
mide15,19,20 in both preventing attacks and improving interictal strength in PP.21 In 2000, 2
randomized, double-blind, placebo-controlled crossover trials22 showed that DCP was effective
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in the prevention of episodic weakness in both
HOP and HYP. These initial crossover trials
had a short follow-up duration and did not
assess quality of life.
We report the results of 2 multicenter ran-
domized, double-blind, placebo-controlled
parallel-group trials of DCP in HOP and in
HYP. A 9-week double-blind phase was fol-
lowed by a 1-year uncontrolled extension
phase during which all participants received
DCP to determine the short- and long-term
effects of DCP.
The study is listed on clinicaltrials.gov
(NCT00494507).
METHODS Primary objective. To determine the short-term
(with Class I evidence) and long-term (with Class II evidence)
effects of DCP on attack frequency and quality of life in HYP
and HOP.
Study design. Two trials (HOP and HYP) were conducted with
the same protocol. Each trial was divided into 2 phases: a random-
ized, double-blind, placebo-controlled 9-week phase followed by
a 1-year uncontrolled extension phase during which all
participants received treatment with DCP. The original design
included an acetazolamide group in each trial. There is a
widespread view among PP patients that acetazolamide is
inferior to DCP (based on personal experience or that of family
members) so the acetazolamide arm had to be abandoned to
facilitate recruitment. Randomization began in April 2007 and
follow-up ended in November 2013.
Standard protocol approvals, registrations, and patient
consents. The protocol was approved by the institutional review
board at each of the 12 participating centers: 10 in the United
States, 1 in the United Kingdom, and 1 in Italy. All participants
gave written informed consent. The trial sponsor (National Insti-
tute of Neurological Disorders and Stroke) established a Data and
Safety Monitoring Board that monitored the study (but did not
review efficacy outcomes).
Participants. Men and women aged 18 years and older with
genetically definite, clinically definite, or clinically probable HOP
or HYP defined according to accepted diagnostic criteria17,23 (table
e-1, appendix e-1, and appendix e-2 on the Neurology® Web site at
Neurology.org) were eligible. Participants were required to have
distinct regular episodes of weakness with an average frequency of
at least 1 per week and fewer than 3 per day either on or off
treatment. Exclusion criteria are set out in table e-2.
Randomization and blinding. Participants were randomized
to DCP or matching placebo (manufactured and supplied by
Taro Pharmaceutical Industries, Haifa Bay, Israel) for the first
9 weeks. Further details of randomization are provided in appen-
dix e-1. An independent blinded physician at each site monitored
the laboratory test results for safety.
Intervention. DCP is 30 times more potent than acetazolamide
in vitro.24 If a participant was taking either acetazolamide or DCP
at enrollment, that medication was immediately stopped and
study drug was substituted; there were no washout periods. Par-
ticipants already taking acetazolamide at enrollment were as-
signed an equivalent dosage of study medication, calculated as
20% of the acetazolamide dosage. Those taking DCP at enroll-
ment received the same dosage of study medication, and those on
no carbonic anhydrase inhibitor received 50 mg bid. HOP pa-
tients continued using potassium supplements as required for
acute attacks. Study drug was started during a 3-day inpatient
visit. If a participant experienced an intolerable adverse event,
dosage reduction was permitted. Participants continued the
double-blind dosage at entry into the 1-year extension phase,
after which dosage adjustment to mimic clinical practice was
permitted.
Outcome variables. Double-blind phase. Details regarding
participant evaluation are provided in appendix e-1. The primary
measure of efficacy was the average number of attacks per week
over the final 8 weeks of the 9-week double-blind phase as cap-
tured by daily telephone report to an electronic diary (interactive
voice response).25 The first week of diary data was excluded to
avoid contamination of the efficacy assessment by the partic-
ipant’s previous treatment, if any. Secondary outcome variables
included severity-weighted attack rate (sum of attack severity
scores from 1 to 10 over the final 8 weeks of the 9-week double-
blind phase divided by the number of weeks), total attack dura-
tion per week (sum of attack durations across all distinct attacks
over the final 8 weeks of the double-blind phase divided by the
number of weeks), and, for the HOP trial only, the endpoint of
acute worsening during the double-blind phase. Acute worsening
was defined as an intolerable increase in frequency or severity of
attacks, necessitating withdrawal from the 9-week double-blind
phase and immediate initiation of the 1-year extension phase.
Additional secondary outcome variables included 9-week changes
in muscle strength measured clinically (manual muscle testing
[MMT]) and quantitatively (maximal voluntary isometric con-
traction testing),26,27 lean body mass (measured by DEXA),28 and
quality of life (Short Form-36 [SF-36] v2).29,30
Safety outcome variables included occurrences of individual
adverse events and changes from baseline to week 9 in vital signs,
laboratory test results, and neuropsychological test results (Sym-
bol Digit Modalities Test,31 Profile of Mood States,32 and
Trail-Making Test Parts A and B).33
One-year uncontrolled extension phase. Outcomes assessed
during the uncontrolled extension phase included attack rate,
severity-weighted attack rate, total attack duration per week
from weeks 54 to 61, and changes from weeks 9 to 61 in measures
of strength and lean body mass. Adverse events and other safety
outcomes were also assessed.
Statistics. Power calculations based on results from a previous
trial22 using a bootstrap method (see supplementary material for
details) yielded a target sample size of 60 HOP participants (30
per group) and 80 HYP participants (40 per group). Due to
delays in recruitment, the trial was stopped before the target
sample sizes were achieved.
Attack rates were compared between the DCP and placebo
groups using Wilcoxon rank sum tests. Participants who reached
the endpoint of acute worsening and those who did not report
any postbaseline data were included by assigning them an attack
rate that was higher than any other observed during the trial. Treat-
ment effects and associated 95% confidence intervals were esti-
mated from the bootstrap distribution of the difference in
medians between the DCP and placebo groups (median and
2.5th and 97.5th percentiles).34 Missing diary entries prior to week
9 were treated as indicating no attack on that day. For participants
who prematurely withdrew from the trial, attack rates were com-
puted using all available diary data up until the time of withdrawal.
Similar analyses were performed for severity-weighted attack rate
and total attack duration per week.
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The proportions of HOP participants on DCP or placebo
reaching the endpoint of acute worsening were compared with
Fisher exact test.
Analysis of covariance, adjusting for the baseline value of the
outcome variable, was used to compare the DCP and placebo
groups with respect to the mean change from baseline to week 9
in strength, lean body mass, and quality of life outcomes. Missing
data at week 9 were accommodated in the analyses using regression-
based multiple imputation with the baseline value of the outcome
variable and treatment group included in the imputation model.35
Changes from baseline to week 9 in vital signs and neuropsycho-
logical test results were analyzed similarly. One-sample t tests were
used to evaluate the significance of mean changes in strength and
lean body mass outcomes from week 9 to week 61. Diary outcomes
and adverse events and other safety data from the uncontrolled
extension phase were analyzed descriptively.
The analyses of data from the 9-week double-blind phase
included all randomized participants in accordance with the
intention-to-treat principle, with one exception noted in the Re-
sults. All p values reported are 2-tailed and a significance level of
5% was used for hypothesis testing.
RESULTS Participant numbers and flow are shown
in the figure. Baseline characteristics are presented
in table 1 and discussed in appendix e-1. The
participant with negative genetics who was with-
drawn from the HOP placebo group represents a
misdiagnosis. This individual is from a family with
5 clinically and genetically affected members so the
negative genetic test suggests a phenocopy rather than
true HOP. Information regarding compliance with
study medication, dosage, and assessment of the
double-blind is presented in appendix e-3.
Double-blind phase. Efficacy. HOP trial. In the double-
blind phase, median attack rate, severity-weighted
attack rate, and attack duration were significantly
lower with DCP than with placebo (table 2). Five
participants from the placebo group but none in the
DCP group reached the endpoint of acute worsening
(p 5 0.01, Fisher exact test).
No treatment effects were apparent on muscle
strength, but the DCP group lost lean body mass
on average compared to a slight increase in the pla-
cebo group (table 2). The mean change in SF-36 v2
Physical Component Summary score indicated qual-
ity of life improvement with DCP compared to pla-
cebo. Beneficial effects of DCP were also apparent on
Figure Flow diagram
*Participants who reached the endpoint of acute worsening during the double-blind phase had an early week 9 visit and moved directly into the 52-week
uncontrolled extension phase. **Data from one participant in the hyperkalemic periodic paralysis (PP) trial were included in the 9-week phase, but not in the
52-week uncontrolled extension phase as the participant had been randomized to acetazolamide in this phase (the trial was initially designed to include a
comparison against acetazolamide; however, the acetazolamide arm had to be abandoned owing to poor recruitment). Forty-five participants were ran-
domized to the hypokalemic PP (HOP) trial, but data from one participant assigned to receive dichlorphenamide (DCP) were not used because the participant
did not meet diagnostic criteria for HOP (this participant is not shown in this figure). The decision to not include the participant was made prior to unblinding.
One participant in the HOP trial assigned to receive placebo in the double-blind phase was mistakenly treated with placebo during the extension phase; data
from this participant were not included in the analyses of data from the extension phase.
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SF-36 v2 subscale scores including Physical Function,
Role-Physical, Bodily Pain, Vitality, and Social Func-
tioning (table 2).
HYP trial. The median severity-weighted attack rate
was significantly lower in the DCP group than in the
placebo group (table 2). Group differences in the median
weekly attack rate and duration did not reach signifi-
cance. No treatment effects were apparent on measures
of muscle strength, lean body mass, and quality of life.
Safety.Table 3 shows the adverse events most com-
monly observed in the double-blind phase.
HOP trial. Paresthesia was more common with DCP
than with placebo (38% vs 5%, p 5 0.01). Cognitive
disorder (21% vs 10%) and dysgeusia (17% vs 0%)
were also more common with DCP, but these group
differences were not statistically significant. One par-
ticipant withdrew from the double-blind phase due to
adverse events, primarily “mental fog.”One participant
developed a rash on DCP. One participant had a seri-
ous adverse event (fractured humerus). DCP was
associated with decreases in blood pressure, pulse,
and weight, as well as worsening in performance on
the Symbol Digit Modalities Test (table 4).
HYP trial. Eight of the 12 participants (67%) on
DCP experienced paresthesias compared to 3 out of
9 (33%) on placebo (p 5 0.20). Cognitive disorder
occurred in 2 DCP-treated participants but in none
on placebo. Two participants developed a rash on
DCP. One of these was a serious adverse event and
required emergency disclosure of treatment assign-
ment; the rash resolved after discontinuation of
DCP and 5 days of hospitalization. DCP was associ-
ated with a decrease in systolic blood pressure and
with worse performance on the Symbol Digit Modal-
ities Test and Trail-Making test (part A) compared
with placebo (table 4).
Open-label uncontrolled extension phase. Efficacy. HOP
trial. At the end of the uncontrolled extension phase
(weeks 54–61), the median (interquartile range
Table 1 Baseline characteristics
Hypokalemic periodic paralysis Hyperkalemic periodic paralysis
Placebo (n 5 20) DCP (n 5 24) Placebo (n 5 9) DCP (n 5 12)
Demographics
Age 44.0 (15.6) 44.8 (14.6) 45.2 (17.7) 40.6 (10.3)
Male, n (%) 16 (80.0) 16 (66.7) 3 (33.3) 6 (50.0)
Caucasian, n (%) 20 (100.0) 20 (83.3) 6 (66.7) 10 (83.3)
Treatment-naive, n (%) 6 (30.0) 6 (25.0) 4 (44.4) 7 (58.3)
Baseline efficacy measures
Attack rate per week, median (IQR) 1.8 (0.5–3.8) 1.1 (0.5–2.1) 4.0 (1.3–6.0) 2.0 (0.8–7.5)
Severity-weighted attack rate, median (IQR) 4.8 (2.3–10.5) 2.6 (1.9–8.0) 9.3 (2.8–12.3) 7.0 (2.3–13.5)
Total attack duration, h/wk, median (IQR) 9.6 (2.6–50.5) 8.3 (3.4–13.9) 19.1 (6.8–37.8) 38.4 (5.1–58.2)
Average MMT score 4.7 (0.3) 4.5 (0.5) 4.4 (0.5) 4.7 (0.3)
Average MVICT score
SD from normal 23.4 (1.4) 23.3 (1.6) 22.9 (1.4) 23.5 (2.4)
% Predicted normal 70.2 (14.1) 72.4 (18.3) 68.8 (20.7) 67.6 (26.3)
DEXA lean body mass, kg 52.8 (11.8) 51.4 (12.0) 46.6 (13.1) 49.0 (12.7)
SF-36 summary scores
Physical component 42.1 (9.8) 39.2 (11.8) 37.3 (11.7) 41.0 (10.8)
Mental component 48.5 (11.9) 52.1 (10.5) 45.9 (14.9) 47.2 (9.7)
Baseline neuropsychology
POMS total mood disturbance 20.9 (32.2) 17.2 (26.1) 29.7 (48.0) 28.7 (30.0)
Symbol Digit Modalities Test 44.4 (10.2) 49.8 (8.4) 53.1 (11.2) 47.8 (11.9)
Trail-making, s
A 30.9 (10.7) 30.8 (9.7) 33.8 (17.4) 34.5 (14.4)
B 80.3 (52.0) 85.7 (46.4) 90.9 (67.6) 96.3 (65.8)
Abbreviations: DCP 5 dichlorphenamide; IQR 5 interquartile range; MMT 5 manual muscle testing; MVICT 5 maximal
voluntary isometric contraction testing; POMS 5 Profile of Mood States; SF-36 5 Short Form-36.
Values reported are mean (SD) unless otherwise indicated.
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Table 2 Treatment effects on efficacy outcomes in the double-blind phase
Hypokalemic periodic paralysis Hyperkalemic periodic paralysis
Placebo (n 5 20) DCP (n 5 24) Treatment effect 95% CI p Value Placebo (n 5 9) DCP (n 5 12) Treatment effect 95% CI p Value
Attack rate per week 2.4 0.3 22.2 26.8 to 20.4 0.02 4.8 0.9 24.1 NA to 0.9 0.10
Severity-weighted attack rate 5.7 0.6 25.2 225.2 to 21.2 0.02 5.7 1.0 24.9 NA to 1.2 0.03
Total attack duration per week 20.0 2.7 219.8 2151.3 to 24.9 0.02 36.3 9.3 222.9 NA to 11.7 0.23
MMT score 20.07 0.04 0.11 20.01 to 0.23 0.08 20.02 0.13 0.15 20.08 to 0.39 0.18
MVICT SD from normal 20.29 20.04 0.25 20.28 to 0.77 0.34 0.55 0.80 0.25 20.42 to 0.91 0.44
MVICT % predicted normal 23.12 20.33 2.79 23.58 to 9.17 0.38 11.86 11.87 0.01 29.77 to 9.79 1.00
DEXA lean body mass, kg 0.55 20.77 21.32 22.63 to 20.01 0.05 21.97 21.15 0.82 20.76 to 2.39 0.28
SF-36 PCS 22.61 4.68 7.29 2.26 to 12.32 0.006 21.15 1.12 2.27 23.08 to 7.61 0.38
SF-36 MCS 26.52 20.96 5.56 20.69 to 11.81 0.08 2.81 20.90 23.71 213.00 to 5.58 0.41
SF-36 Physical Functioning 26.94 4.93 11.87 2.36 to 21.38 0.02 4.16 6.16 2.00 216.35 to 20.34 0.82
SF-36 Role-Physical 28.93 14.62 23.55 10.51 to 36.59 0.0008 24.55 2.92 7.47 215.19 to 30.13 0.49
SF-36 Bodily Pain 212.25 6.02 18.27 2.88 to 33.66 0.02 210.63 24.47 6.16 213.07 to 25.38 0.50
SF-36 General Health 23.60 5.27 8.88 21.00 to 18.75 0.08 7.43 6.41 21.01 216.43 to 14.40 0.89
SF-36 Vitality 212.54 2.43 14.97 4.48 to 25.46 0.006 3.07 2.73 20.35 213.25 to 12.56 0.95
SF-36 Social Functioning 212.81 9.46 22.26 8.78 to 35.74 0.002 8.13 23.19 211.32 237.32 to 14.68 0.37
SF-36 Role-Emotional 210.72 0.08 10.81 22.77 to 24.39 0.12 27.17 2.43 9.60 210.04 to 29.24 0.31
SF-36 Mental Health 29.68 22.25 7.43 22.36 to 17.21 0.13 9.02 22.83 211.85 225.44 to 1.75 0.08
Abbreviations: CI 5 confidence interval; DCP 5 dichlorphenamide; MCS 5 mental component summary; MMT 5 manual muscle testing; MVICT 5 maximum voluntary isometric contraction testing; PCS 5 physical
component summary; SF-36 5 Short Form-36.
For diary outcomes (attack rates and duration), values presented are median values for each group over weeks 2–9. Treatment effects (DCP 2 placebo) are computed as the median of the bootstrap distribution of
the treatment group difference in median response; the 95% CIs are computed using the 2.5 and 97.5 percentiles of this bootstrap distribution. NA indicates that the 2.5 percentile of the bootstrap distribution
was not available because 2 of the 9 participants in the placebo group reached the endpoint of acute worsening and thus were assigned an arbitrarily large attack rate (or duration) for purposes of analysis. p Values
are computed using a Wilcoxon rank sum test, with those who reach the endpoint of acute worsening assigned an arbitrarily large attack rate (or duration) for purposes of analysis. For all other (non-diary) outcomes,
values presented are mean changes from baseline to week 9, treatment effects (DCP 2 placebo), 95% CIs, and p values, all obtained from an analysis of covariance model that adjusts for the baseline value of the
outcome variable. Missing data are accommodated using multiple imputation (see text for details).
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[IQR]) attack rate was reduced to 0.2 (0.0–1.0) in
participants who had been on placebo (n 5 14) and
0.0 (0.0–0.1) in participants who had been on DCP
(n 5 17) in the double-blind phase. The median
(IQR) severity-weighted attack rate was 0.4 (0.0–
2.6) in participants who had been on placebo and
0.0 (0.0–0.3) in participants who had been on
DCP. The weekly total attack duration was 2.1
(0.0–21.4) in participants who had been on placebo
and 0.0 (0.0–0.3) in participants who had been on
DCP. From weeks 9–61, there was a small mean
increase in composite MMT score (n 5 28; 0.07
points, 95% confidence interval [CI] 0.004–0.14,
p 5 0.04) that was not corroborated by quantitative
muscle strength testing. There was a reduction in
mean lean body mass at week 61 compared to week
9 (n 5 24; 22.00 kg, 95% CI 23.31 to 20.69 kg,
p 5 0.004).
HYP trial. At the end of the uncontrolled extension
phase (weeks 54–61), the median (IQR) attack rate
was reduced to 0.9 (0.0–1.4) in participants who had
been on placebo (n 5 7) and 0.3 (0.1–1.3) in partic-
ipants who had been on DCP (n5 9) in the double-
blind phase. The median (IQR) severity-weighted
attack rate was 2.4 (0.0–3.9) in participants who
had been on placebo and 0.9 (0.3–2.5) in participants
who had been on DCP. The weekly total attack dura-
tion was 8.0 (0.0–107.6) in participants who had
been on placebo and 9.9 (0.2–21.0) in participants
who had been on DCP. No significant changes in
Table 3 Adverse events in the double-blind phase
Hypokalemic periodic
paralysis
Hyperkalemic periodic
paralysis Both trials
Placebo (n 5 20) DCP (n 5 24) Placebo (n 5 9) DCP (n 5 12) Placebo (n 5 29) DCP (n 5 36)
Paresthesia 1 (5) 9 (38) 3 (33) 8 (67) 4 (14) 17 (47)
Cognitive disorder 2 (10) 5 (21) — 2 (17) 2 (7) 7 (19)
Dysgeusia — 4 (17) — — — 4 (11)
Headache 1 (5) 3 (13) — — 1 (3) 3 (8)
Fall 2 (10) 1 (4) — — 2 (7) 1 (3)
Fatigue — 3 (13) — — — 3 (8)
Hypoesthesia — 3 (13) — — — 3 (8)
Muscle Spasms — 3 (13) — — — 3 (8)
Nausea — — — 2 (17) — 2 (6)
Rash — — — 2 (17) — 2 (6)
Weight loss — — — 2 (17) — 2 (6)
Abbreviation: DCP 5 dichlorphenamide.
Values presented are the number (%) of participants who reported at least one occurrence of the event.
Table 4 Treatment effects on neuropsychological tests, mood, and vital signs in the double-blind phase
Hypokalemic periodic paralysis Hyperkalemic periodic paralysis
Placebo
(n 5 20)
DCP
(n 5 24)
Treatment
effect 95% CI p Value
Placebo
(n 5 9)
DCP
(n 5 12)
Treatment
effect 95% CI p Value
Symbol Digit Modalities Test 5.9 22.9 28.8 214.5 to23.1 0.003 1.7 26.3 28.0 214.5 to21.5 0.02
Trail-Making Part A (Log) 20.06 0.09 0.15 20.06 to 0.36 0.15 20.25 0.09 0.34 0.08 to 0.61 0.01
Trail-Making Part B (Log) 20.06 20.13 0.07 20.18 to 0.31 0.58 20.19 0.14 0.33 20.02 to 0.68 0.06
POMS Total mood disturbance 5.3 21.9 27.2 221.7 to 7.3 0.32 26.0 26.9 20.9 223.1 to 21.3 0.93
Systolic blood pressure 8.2 24.9 213.1 220.4 to25.8 0.0008 2.3 27.1 29.4 218.3 to20.6 0.04
Diastolic blood pressure 1.9 25.5 27.4 212.5 to22.3 0.006 2.5 24.1 26.6 218.0 to 4.8 0.24
Pulse 4.6 23.4 28.0 215.2 to20.9 0.03 1.4 22.9 24.3 215.4 to 6.8 0.43
Weight, kg 0.2 21.4 21.6 23.0 to 20.3 0.02 20.4 22.1 21.7 23.9 to 0.5 0.13
Abbreviations: CI 5 confidence interval; DCP 5 dichlorphenamide; POMS 5 Profile of Mood States.
Values presented are mean changes from baseline to week 9, treatment effects (DCP2 placebo), 95% confidence intervals, and p values, all obtained from
an analysis of covariance model that adjusts for the baseline value of the outcome variable. Missing data are accommodated using multiple imputation (see
text for details).
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muscle strength scores or muscle mass were observed
during the extension phase.
Safety. HOP trial. Of the adverse events during the
extension phase that were classified as possibly, prob-
ably, or definitely related to treatment (table e-3), the
most common was paresthesia, which was assigned in
10 of 40 participants (25%) as probably related and
in 2 of 40 (5%) as possibly related. The second most
common was cognitive disorder. Of the 39 partici-
pants who underwent the final assessment for renal
tract calculi, 7 developed new calculi during the trial
and 2 showed an increase in size or number of preex-
isting calculi.
Ten HOP participants withdrew from the exten-
sion phase of the trial. One of these was discovered
to have pancreatic cancer. Five experienced tiredness,
fatigue, or mental slowness sufficient to impair per-
formance at work. One, who had never tried carbonic
anhydrase inhibitors, experienced worsening attacks
and was discovered to have a sodium channel muta-
tion (R222W mutation). The drug was stopped and
the participant withdrawn from the trial. One partic-
ipant withdrew due to painful kidney stones, and 2
others withdrew for intolerable but unspecified
adverse events.
HYP trial. Of the adverse events during the exten-
sion phase that were classified as possibly, probably,
or definitely related to treatment (table e-3), the
most common was paresthesia, which was assigned
in 2 of 17 participants (11.8%) as possibly related,
in 6 of 17 (35.3%) as probably related, and in 1 of
17 (5.9%) as definitely related. The only other
adverse event that occurred in more than one partic-
ipant was memory impairment, which was assigned
in 1 of 17 (6%) as possibly related to treatment and
in 1 of 17 (6%) as probably related to treatment. Of
the 14 participants who underwent the final assess-
ment for renal tract calculi, only 1 developed new
calculi.
DISCUSSION This parallel-group trial strengthens
the evidence22 for the beneficial effect of DCP in
HOP. In addition, it shows that DCP improves
quality of life in HOP, and that its efficacy is
maintained in the long term.
The majority of HOP participants on DCP in this
trial experienced less than 1 attack per week compared
to more than 2 attacks per week on placebo. A quarter
of the HOP participants on placebo but none of those
on DCP had intolerable attacks and had to be moved
into the extension phase before completing the 9-
week double-blind phase. Upon entering the uncon-
trolled phase, HOP participants previously treated
with placebo appeared to benefit substantially from
the introduction of DCP, and there was continued
control of attacks in participants already taking
DCP. This is an important observation suggesting
persisting efficacy of DCP well beyond the time win-
dow of previous trials of this agent.
For the majority of participants, DCP was well-
tolerated, and the benefits on quality of life appear
to outweigh the side effects. Twelve of the 65 ran-
domized participants (18%; 9 HOP and 3 HYP)
withdrew from the trials due to adverse events
while being treated with DCP, most during the
long-term extension phase (8 HOP and 1 HYP).
In both trials, the most common adverse event
was paresthesia, but this was transitory and never
the cause of withdrawal. Kidney stones, another
potential problem with carbonic anhydrase inhibi-
tors,36 were a cause of drop-out in only one partic-
ipant. The second most common adverse event was
slowed cognition; patients, particularly those in
cognitively demanding professions, should be
counseled about this side effect. There was an
apparent decrease in muscle mass associated with
DCP in the HOP trial; however, this may be due to
an artifact (reduced muscle water content) of DCP-
induced diuresis.
The main shortcomings of these trials were the
lack of comparison against acetazolamide and the
limited number of participants. The PP are exceed-
ingly rare diseases (HOP prevalence 1/100,000;
HYP prevalence 1/250,000).1–3 In the United
States, inclusion of acetazolamide in the original
design discouraged many potential participants. In
the European Union, local ethics and research and
development bureaucracy was a major barrier, with
Italy and the United Kingdom entering the trial late,
and France not at all.
Insufficient numbers of participants precluded
analysis by genetic subgroup. Mutations were identi-
fied in 75% of HOP participants and in 67% of HYP
participants either prior to or following enrollment.
The most common were T704M in the HYP trial
and R528H and R1239H in the HOP trial. Qualita-
tive assessment of the effect of DCP treatment in sub-
groups defined by mutation type did not reveal any
major subgroup differences in the effect of DCP on
attacks other than worsening of attacks in the HOP
patient with NaV1.4 pR222W. Genetic confirmation
of included patients was lacking in more than 25%.
This is in agreement with published data3 and sup-
ports the idea that the study reflects patients with PP
in the general population.
DCP was available for off-label prescription for PP
until 2002, when the drug stopped being marketed
for glaucoma. As a consequence, DCP became
unavailable for patients with PP in many countries
until Food and Drug Administration approval in
August 2015. Our findings support the idea that
DCP would benefit many patients with PP.
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